Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Spero Therapeutics (SPRO) EBITDA Margin (2016 - 2025)

Spero Therapeutics' EBITDA Margin history spans 10 years, with the latest figure at 66.79% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 3262448.0% year-over-year to 66.79%; the TTM value through Dec 2025 reached 9.0%, up 29639.0%, while the annual FY2025 figure was 13.42%, 1849483.0% up from the prior year.
  • EBITDA Margin reached 66.79% in Q4 2025 per SPRO's latest filing, up from 145.46% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 3180.93% in Q3 2021 to a low of 32557.69% in Q4 2024.
  • Average EBITDA Margin over 5 years is 2736.04%, with a median of 218.86% recorded in 2024.
  • Peak YoY movement for EBITDA Margin: surged 3336721bps in 2021, then crashed -3262865bps in 2024.
  • A 5-year view of EBITDA Margin shows it stood at 235.01% in 2021, then crashed by -32bps to 159.59% in 2022, then plummeted by -56bps to 70.95% in 2023, then tumbled by -45985bps to 32557.69% in 2024, then surged by 100bps to 66.79% in 2025.
  • Per Business Quant, the three most recent readings for SPRO's EBITDA Margin are 66.79% (Q4 2025), 145.46% (Q3 2025), and 20.71% (Q2 2025).